Nemaura Medical announces that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. The Company plans to continue with its commercial endeavours while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearing Panel’s decision.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NMRD:
- Nemaura Medical secures $10M non-dilutive credit facility
- Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth
- Nemaura Medical rating moved to under review at H.C. Wainwright
- Nemaura launches direct to consumer offering of metabolic health program
- Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs
